SI1603877T1 - Novi derivati aminopiridina kot antagonisti mGiuR5 - Google Patents

Novi derivati aminopiridina kot antagonisti mGiuR5

Info

Publication number
SI1603877T1
SI1603877T1 SI200431006T SI200431006T SI1603877T1 SI 1603877 T1 SI1603877 T1 SI 1603877T1 SI 200431006 T SI200431006 T SI 200431006T SI 200431006 T SI200431006 T SI 200431006T SI 1603877 T1 SI1603877 T1 SI 1603877T1
Authority
SI
Slovenia
Prior art keywords
aminopyridine derivatives
novel aminopyridine
mgiur5
antagonists
novel
Prior art date
Application number
SI200431006T
Other languages
English (en)
Slovenian (sl)
Inventor
Christelle Bolea
Vincent Mutel
Jean-Philippe Rocher
Anne-Sophie Bessis
Poul Emmanuel Le
Original Assignee
Addex Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0304901A external-priority patent/GB0304901D0/en
Priority claimed from GB0316430A external-priority patent/GB0316430D0/en
Application filed by Addex Pharma Sa filed Critical Addex Pharma Sa
Publication of SI1603877T1 publication Critical patent/SI1603877T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SI200431006T 2003-03-04 2004-03-04 Novi derivati aminopiridina kot antagonisti mGiuR5 SI1603877T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0304901A GB0304901D0 (en) 2003-03-04 2003-03-04 Novel aminopyridine derivatives as mGIuR5 antagonists
GB0316430A GB0316430D0 (en) 2003-07-14 2003-07-14 Aminopyridine derivatives
PCT/IB2004/000745 WO2004078728A1 (en) 2003-03-04 2004-03-04 NOVEL AMINOPYRIDINE DERIVATIVES AS mGIuR5 ANTAGONISTS
EP04717193A EP1603877B1 (en) 2003-03-04 2004-03-04 NOVEL AMINOPYRIDINE DERIVATIVES AS mGIuR5 ANTAGONISTS

Publications (1)

Publication Number Publication Date
SI1603877T1 true SI1603877T1 (sl) 2009-04-30

Family

ID=32964064

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200431006T SI1603877T1 (sl) 2003-03-04 2004-03-04 Novi derivati aminopiridina kot antagonisti mGiuR5

Country Status (16)

Country Link
US (2) US7205411B2 (cg-RX-API-DMAC7.html)
EP (2) EP2028180A1 (cg-RX-API-DMAC7.html)
JP (1) JP2006519251A (cg-RX-API-DMAC7.html)
AT (1) ATE415390T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004218180B2 (cg-RX-API-DMAC7.html)
CA (1) CA2517083A1 (cg-RX-API-DMAC7.html)
CY (1) CY1108837T1 (cg-RX-API-DMAC7.html)
DE (1) DE602004017966D1 (cg-RX-API-DMAC7.html)
DK (1) DK1603877T3 (cg-RX-API-DMAC7.html)
ES (1) ES2316968T3 (cg-RX-API-DMAC7.html)
PL (1) PL1603877T3 (cg-RX-API-DMAC7.html)
PT (1) PT1603877E (cg-RX-API-DMAC7.html)
RU (1) RU2330020C2 (cg-RX-API-DMAC7.html)
SI (1) SI1603877T1 (cg-RX-API-DMAC7.html)
UA (1) UA81464C2 (cg-RX-API-DMAC7.html)
WO (1) WO2004078728A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0413605D0 (en) 2004-06-17 2004-07-21 Addex Pharmaceuticals Sa Novel compounds
AU2006240217A1 (en) * 2005-04-22 2006-11-02 Merck & Co., Inc. Phenyl ethyne compounds
WO2007035823A2 (en) * 2005-09-20 2007-03-29 Molecular Neuroimaging, Llc Partial mglur5 antagonists and methods of use thereof
DE102005062987A1 (de) * 2005-12-28 2007-07-05 Grünenthal GmbH Substituierte Propiolsäureamide und ihre Verwendung zur Herstellung von Arzneimitteln
EP2272509A1 (en) * 2006-09-11 2011-01-12 Novartis AG New Uses of metabotropic glutamate receptors
EA201391348A8 (ru) 2011-03-18 2014-11-28 Новартис Аг КОМБИНАЦИИ АКТИВАТОРОВ АЛЬФА-7 НИКОТИНОВОГО АЦЕТИЛХОЛИНОВОГО РЕЦЕПТОРА И АНТАГОНИСТОВ mGluR5, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ПРИМЕНЕНИЯ ПРИ ВЫЗВАННОЙ ДОПАМИНОМ ДИСКИНЕЗИИ, СВЯЗАННОЙ С БОЛЕЗНЬЮ ПАРКИНСОНА

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6028963A (ja) * 1983-07-27 1985-02-14 Takeda Chem Ind Ltd 置換ビニル誘導体
TW544448B (en) 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
DE10009000A1 (de) 2000-02-25 2001-08-30 Basf Ag Verfahren zur Herstellung substituierter Indole
NZ525917A (en) 2000-12-04 2005-11-25 F Phenylethenyl or phenylethinyl derivatives as glutamate receptor antagonists and their use in treating mGLuR5 receptor mediated disorders

Also Published As

Publication number Publication date
AU2004218180B2 (en) 2009-11-12
EP1603877A1 (en) 2005-12-14
DK1603877T3 (da) 2009-03-09
RU2330020C2 (ru) 2008-07-27
US20080004316A1 (en) 2008-01-03
ES2316968T3 (es) 2009-04-16
PT1603877E (pt) 2009-02-11
EP2028180A1 (en) 2009-02-25
RU2005130647A (ru) 2006-04-10
US20060030601A1 (en) 2006-02-09
UA81464C2 (en) 2008-01-10
CA2517083A1 (en) 2004-09-16
ATE415390T1 (de) 2008-12-15
AU2004218180A1 (en) 2004-09-16
PL1603877T3 (pl) 2009-05-29
EP1603877B1 (en) 2008-11-26
WO2004078728A1 (en) 2004-09-16
DE602004017966D1 (de) 2009-01-08
CY1108837T1 (el) 2014-07-02
US7205411B2 (en) 2007-04-17
JP2006519251A (ja) 2006-08-24

Similar Documents

Publication Publication Date Title
GB0325956D0 (en) Novel compounds
UA87856C2 (ru) Алкильные производные как модуляторы метаботропных рецепторов глутамата
MY135841A (en) Novel benzodioxoles
MY135686A (en) Indole derivatives useful as histamine h3 antagonists
SE0201635D0 (sv) Novel compounds
EA200500342A1 (ru) Гетероциклические замещённые пиперазины для лечения шизофрении
DE69328975D1 (de) Aminomethylen substituierte heterocyclische verbindungen und ihre verwendung alssubstanz p antagonisten
TW200602322A (en) Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
ATE272398T1 (de) Verwendung von ep4 rezeptorliganden zur behandlung von neuropathischen schmerz
IL197642A (en) Heterocyclic Derivatives and Their Uses to Prepare Pharmaceutical Preparations for the Treatment of Opioid Receptor Syndromes
CY1108837T1 (el) ΝΕΑ ΠΑΡΑΓΩΓΑ ΑΜΙΝΟΠΥΡΙΔΙΝΗΣ ΩΣ ΑΝΤΑΓΩΝΙΣΤΕΣ mGluR5
ATE272617T1 (de) Sulfonamid-derivate
EA200801734A1 (ru) Производные n-тиазол-2-илбензамида
BG105710A (en) 5ht1 antagonists for antidepressant therapy
BR0201569A (pt) 4-(2-piridil) piperizinas possuindo uma atividade agonista do receptor 5ht7
DE60204882D1 (de) Zykloalkenylsulfonamidderivate
EA200401099A1 (ru) Производные гетероциклического амида
NO20081529L (no) Naftyridinderivater
DK1373218T3 (da) Imidazolylderivater til anvendelse som histamin H3-receptorligander
ATE283269T1 (de) 5-(heteroaryl)alkyl)-3-oxo-pyrido(1,2- a)benzimidazol-4-carboxamid (pbi) derivate zur behandlung von störungen des zentralen nervensystems
BG105247A (en) N-substituted azabicycloheptane derivatives, production and use thereof
WO2002040465A3 (en) Aryloxy piperidinyl indoles for treating depression
EA200501053A1 (ru) Производные 1,2,4-триаминобензола, пригодные для лечения расстройств центральной нервной системы